In the area of primary resistance, activating mutations in KRAS track with poor responses to EGFR inhibition with the monoclonal antibodies (mAbs) cetuximab and panitumumab, or small molecule EGFR inhibitors like gefitinib and erlotinib, in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients6,7,8,9,10. Here, KRAS is linked to colorectal carcinoma.